NeuroX1
Techstars '24Austin, US · Founded 2021 · 2 known investors
NeuroX1 is an Austin-based biotech building a generative-AI target ID and drug discovery platform for neurological disorders.
Also known as Neurox1
Investors · 2
Company profile
researched Aug 2026NeuroX1 is a privately held, Austin, Texas-based biotechnology company developing a target identification and drug discovery platform that applies proprietary generative AI algorithms to design therapeutics for neurological and neurodegenerative disorders. The platform combines target identification, computational biology, machine learning and generative chemistry, including a generative chemistry system referred to as Chiron, to identify disease drivers and design small molecules in silico.
The company's activity is discovery- and preclinical-stage rather than clinical. Its pipeline consists of several preclinical assets developed alongside pharmaceutical companies and academic institutions, spanning neurodegenerative, neurological, rare/orphan and brain-cancer indications. Reported work includes eight BTK1 inhibitors for multiple sclerosis designed with more favorable in silico characteristics than a compound in phase 3 development at Merck KGaA, plus exploratory programs on neuro-targets with two academic groups.
Founding story
NeuroX1 was founded in 2021 by Max Dordevic and Conner Myers, with Dordevic serving as chief executive officer and Myers as chief informatics officer; a co-founder and chief technology officer, Lucas Myers, is also listed.
Business model
NeuroX1 operates as a preclinical therapeutics discovery company, generating assets through its computational platform and advancing them in partnership with pharmaceutical companies and academic institutions rather than through diagnostics or device sales.
Traction
Reported traction includes partnerships with several biopharma companies and academic institutions, a perpetual agreement with an academic center/brain bank for diseased brain tissue, work with two academic groups on neuro-targets, eight BTK1 inhibitors created for multiple sclerosis, a collaboration with Everlum Bio in pediatric rare disease and a collaboration with Entropy Bio in neuro-oncology.
Latest developments
As of a 2026 company profile, NeuroX1 was listed as actively raising a seed round with a $3.0 million target, with Capital Factory Partners Fund 2022 named in its profile.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
NeuroX1 positions itself in computational and generative-AI drug discovery for neurological disease, addressing markets it sizes at roughly $52B for neurodegenerative disease, $82B for neurological disease, additional billions in brain cancer, and $125.3B by 2030 across all neurological disorders including rare and orphan diseases.
The company emphasizes in silico small-molecule design and preclinical target discovery over diagnostics or medical devices, citing BTK1 inhibitors for multiple sclerosis with more favorable in silico profiles than a phase 3 comparator, and proprietary generative AI algorithms.
Technology
The core platform pairs a target identification system with generative chemistry. Machine learning and computational biology are used to identify drivers of neurological and neurodegenerative disease, and a proprietary generative chemistry engine called Chiron designs novel small molecules in silico. The target ID system draws on diseased brain tissue supplied under a perpetual agreement with an academic center/brain bank.
Go-to-market
Development proceeds through research collaborations and partnerships with biopharma companies and academic groups, which validate targets and compounds ahead of later-stage development.
Pharmaceutical and biopharma companies and academic research institutions seeking preclinical small-molecule assets and targets in neurology, neurodegeneration, rare disease and neuro-oncology.
Geography
Headquartered in Austin, Texas, United States.
History
The company was founded in 2021 and has remained a small private team, with an early-stage preclinical pipeline built through pharma and academic partnerships.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsNeuroX1 reports a partnership with Entropy Bio to work on neuro-oncology indications.
NeuroX1 reports a partnership with Everlum Bio focused on pediatric rare diseases.
Perpetual agreement with an academic center/brain bank providing diseased brain tissue for the company's target identification system.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- Neurox1 — Whiteford Research Biobasebiobase.whitefordresearch.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does NeuroX1 do?
- NeuroX1 is an Austin-based biotech building a generative-AI target ID and drug discovery platform for neurological disorders.
- Who are NeuroX1's investors?
- NeuroX1's investors include Techstars, Vibe Capital.
- Where is NeuroX1 headquartered?
- NeuroX1 is headquartered in Austin, US.